Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C49085
http://purl.obolibrary.org/obo/NCIT_C49085
|
|---|---|
| Preferred Name | Tremelimumab |
| Definitions |
A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition. |
|---|---|
| prefLabel | Tremelimumab
|
| label | Tremelimumab
|
| PDQ_Closed_Trial_Search_ID | 448620
|
| code | C49085
|
| Has_Target | |
| prefixIRI | NCIT:C49085
|
| in_subset |
See more
See less
|
| Display_Name | Tremelimumab
|
| Preferred_Name | Tremelimumab
|
| FDA_UNII_Code | QEN1X95CIX
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Tremelimumab
|
| CAS_Registry | 745013-59-6
|
| NCI_Drug_Dictionary_ID | 448620
|
| Legacy Concept Name | Anti-CTLA4_Human_Monoclonal_Antibody_CP-675_206
|
| type | |
| ALT_DEFINITION | A monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. Ticilimumab is made in the laboratory and binds to a protein called CTLA-4 on T cells (a type of white blood cell). CTLA-4 is involved in preventing the activation of T-cells. Ticilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of immunomodulatory agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 448620
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2351038
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |